MetaCap

Anixa Biosciences (ANIX) vs Nkarta (NKTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Nkarta (NKTX) has outperformed Anixa Biosciences (ANIX) over the past year, losing 36.9% versus a loss of 43.8%. Over five years, ANIX leads with a -38.7% price change compared with -93.0% for NKTX. Anixa Biosciences is the larger company by market cap ($84.8 million vs $81.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANIX-43.78%NKTX-36.94%
+111%+29%-53%
Nov 21, 20251 yearNov 20, 2026
ANIX-40.92%NKTX-93.47%
+51%-24%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANIX versus NKTX key metrics
MetricANIXNKTX
Share price$2.44$1.14
Market cap$84.82M$81.29M
1-day change-6.15%+1.34%
YTD return-21.79%-38.65%
1-year return-43.78%-36.94%
5-year return-38.69%-93.05%
EPS (TTM)$-0.32$-1.73
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Net income (latest FY)$-10.93M$-104.08M
52-week high$5.46$3.72
52-week low$2.32$1.11
Distance from 52-week high-55.31%-69.49%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+296.31%+825.11%
Average volume282.29K1.02M
Shares outstanding34.76M71.62M
Employees4108
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Anixa Biosciences

ANIX stock →

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

About Nkarta

NKTX stock →

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.

Health Care · Biotechnology: Pharmaceutical Preparations · 108 employees

ANIX vs NKTX FAQ

Which is bigger, Anixa Biosciences or Nkarta?

Anixa Biosciences (ANIX) is larger, with a market capitalization of $84.82M compared with $81.29M for Nkarta (NKTX).

Which stock has performed better over the past year, ANIX or NKTX?

NKTX returned -36.94% over the past 12 months, compared with -43.78% for ANIX (price return, excluding dividends). Past performance does not predict future results.

Are Anixa Biosciences and Nkarta in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons